GlassScriptPhysician profile
Ryan Alexander Goldfine
NPI 1194107425
$1,395.05
in general payments reported to CMS, 2019-2025
21 companies · $285 in 2025
The $285 reported for 2025 was less than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $291 · 2022: $363 · 2023: $195 · 2024: $261 · 2025: $285.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $740.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $225.44 | 2022-2023 | Senza |
| Smith+Nephew, INC. | $179.57 | 2021-2025 | Collagenase Santyl |
| Medtronic, INC. | $136.48 | 2023-2024 | Hawkone, Venaseal |
| Lifenet Health | $118.04 | 2025 | Theragenesis Wound Matrix |
| Horizon Therapeutics Plc | $104.27 | 2021-2022 | |
| Triad Life Sciences INC. | $103.11 | 2022 | |
| Treace Medical Concepts, INC. | $100.50 | 2025 | |
| Polymedics Innovations INC. | $78.78 | 2023 | |
| Reprise Biomedical, INC. | $49.60 | 2021-2024 | Miro3d |
| Kerecis Limited | $48.53 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide, Kerecis Omega3 Surgiclose |
| Djo, LLC | $42.61 | 2024-2025 | Cmf |
| Abbott Laboratories | $25.24 | 2025 | Proclaim |
| Organogenesis INC. | $25.23 | 2021 | |
| Zimvie INC. | $23.33 | 2022 | |
| Progenacare Global, LLC | $23.28 | 2023 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $22.58 | 2023 | Seglentis |
| Abbvie INC. | $21.19 | 2023 | |
| Paratek Pharmaceuticals, INC. | $17.49 | 2024 | Nuzyra |
| Convatec INC. | $17.05 | 2023 | |
| Integra Lifesciences Corporation | $16.99 | 2021 | |
| Ibsa Pharma INC. | $15.74 | 2024 | Licart, Tirosint |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Goldfine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.